Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
ImmunoPrecise Antibodies Ltd. (IPA) will showcase a pre-recorded presentation featuring CEO Dr. Jennifer Bath at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available for on-demand viewing starting January 11 at 6:00 a.m. ET for 30 days. In addition, management will engage in one-on-one investor meetings during the Stern IR Virtual Corporate Access Event. IPA specializes in therapeutic antibody discovery, offering comprehensive solutions to accelerate drug development.
ImmunoPrecise Antibodies Ltd. (IPA) has joined the COVABELP consortium with Radboud University Medical Center and Eindhoven University of Technology. The consortium received €350,000 from Health Holland to develop a SARS-CoV-2-specific therapeutic nanomedicine for nasal inhalation, aiming to induce immunity and facilitate virus detection. IPA's expertise in antibody isolation will bolster this initiative. The intellectual property generated will be co-owned, with IPA retaining first rights for commercialization. This collaboration is a significant step toward innovative therapeutic solutions for future pandemics.